project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9M4; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.8; concentration: 0.15; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.74; rna integrity number: 8.6; age at index: 65; days to birth: -24030; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1947; age at diagnosis: 24030; ajcc clinical m: M0; ajcc clinical t: T2a; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 547.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 509; initial weight: 150.0; sample id: 611eed41-249d-49bc-b64a-cfb19abe7f47; sample submitter id: TCGA-ZG-A9M4-01A; portion id: 018e196a-d02f-478e-9e21-bbac90177a48; portion submitter id: TCGA-ZG-A9M4-01A-11; slide id: d8da1306-a333-4aee-87de-ca60405f0585; slide submitter id: TCGA-ZG-A9M4-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 40.0; percent tumor cells: 60.0; percent tumor nuclei: 70.0; section location: TOP;